1. 108P Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab. (December 2022) Authors: Persano, M.; Rimini, M.; Cascinu, S.; Scartozzi, M.; Casadei Gardini, A. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 111P Identification of atezolizumab plus bevacizumab prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma: The ABE index. (December 2022) Authors: Persano, M.; Rimini, M.; Cascinu, S.; Scartozzi, M.; Casadei Gardini, A. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 65P Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population. (December 2022) Authors: Rimini, M.; Casadei Gardini, A.; Persano, M.; Suda, G.; Tada, T.; Shimose, S.; Kudo, M.; Cheon, J.; Finkelmeier, F.; Rimassa, L.; Presa, J.; Masi, G.; Yoo, C.; Lonardi, S.; Tovoli, F.; Piscaglia, F.; Iavarone, M.A.; Scartozzi, M.; Burgio, V.; Cascinu, S. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 67P Real-world data for atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. (December 2022) Authors: Persano, M.; Rimini, M.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Cheon, J.; Finkelmeier, F.; Rimassa, L.; Presa, J.; Masi, G.; Yoo, C.; Lonardi, S.; Piscaglia, F.; Burgio, V.; Scartozzi, M.; Cascinu, S.; Casadei Gardini, A. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 78P Clinical outcomes with atezolizumab plus bevacizumab (AB) or lenvatinib (L) in hepatocellular carcinoma (HCC). (December 2022) Authors: Persano, M.; Rimini, M.; Cascinu, S.; Scartozzi, M.; Casadei Gardini, A. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Estrogens as Antioxidant Modulators in Human Fertility. (20th November 2013) Authors: Mancini, A.; Raimondo, S.; Persano, M.; Di Segni, C.; Cammarano, M.; Gadotti, G.; Silvestrini, A.; Pontecorvi, A.; Meucci, E. Other Names: Dufau Maria L. Academic Editor. Journal: International journal of endocrinology Issue: Volume 2013(2013) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗